tallózása szerző szerint "Taylor MD"

A találatok rendezése: Rendezés: Találatok:

  • DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. 
    Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami, Miklós; Hauser, Péter; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC (2013)
    Molecular subclassification is rapidly informing the clinical management of medulloblastoma. However, the disease remains associated with poor outcomes and therapy-associated late effects, and the majority of patients are ...
  • Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma 
    Northcott PA; Lee C; Zichner T; Stutz AM; Erkek S; Kawauchi D; Shih DJ; Hovestadt V; Zapatka M; Sturm D; Jones DT; Kool M; Remke M; Cavalli FM; Zuyderduyn S; Bader GD; VandenBerg S; Esparza LA; Ryzhova M; Wang W; Wittmann A; Stark S; Sieber L; Seker-Cin H; Linke L; Kratochwil F; Jager N; Buchhalter I; Imbusch CD; Zipprich G; Raeder B; Schmidt S; Diessl N; Wolf S; Wiemann S; Brors B; Lawerenz C; Eils J; Warnatz HJ; Risch T; Yaspo ML; Weber UD; Bartholomae CC; von Kalle C; Turányi, Eszter; Hauser, Péter; Sanden E; Darabi A; Siesjo P; Sterba J; Zitterbart K; Sumerauer D; van Sluis P; Versteeg R; Volckmann R; Koster J; Schuhmann MU; Ebinger M; Grimes HL; Robinson GW; Gajjar A; Mynarek M; von Hoff K; Rutkowski S; Pietsch T; Scheurlen W; Felsberg J; Reifenberger G; Kulozik AE; von Deimling A; Witt O; Eils R; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Korbel JO; Wechsler-Reya RJ; Pfister SM (2014)
    Medulloblastoma is a highly malignant paediatric brain tumour currently treated with a combination of surgery, radiation and chemotherapy, posing a considerable burden of toxicity to the developing child. Genomics has ...
  • Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas 
    Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Stucklin AG; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown, T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang SY; Snuderl M; Rao AN; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Conter CF; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser, Péter; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen SY; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U (2017)
    Purpose BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and ...